Lewandrowski Kent, Chen Ahchean, Januzzi James
Division of Laboratory Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
Am J Clin Pathol. 2002 Dec;118 Suppl:S93-9. doi: 10.1309/3EK7-YVV9-228C-E1XT.
Blood testing for biomarkers of myocardial injury plays an increasingly important role for the evaluation, diagnosis, and triage of patients with chest pain. The guidelines for the diagnosis of myocardial infarction (MI) have recently changed and prominently incorporate the results of cardiac marker testing in the clinical definition of MI. We review these updated guidelines for MI definition as it pertains to cardiac biomarker testing and further compare the differing biology and release kinetics of clinically relevant biomarkers. Finally, we define the contemporary use of cardiac biomarker testing for patients with chest pain, including appropriate integration of point-of-care testing into day-to-day clinical use.
检测心肌损伤生物标志物的血液检测在胸痛患者的评估、诊断和分诊中发挥着越来越重要的作用。心肌梗死（MI）的诊断指南最近有所变化，并且在MI的临床定义中显著纳入了心脏标志物检测结果。我们回顾这些与心脏生物标志物检测相关的MI定义的更新指南，并进一步比较临床相关生物标志物的不同生物学特性和释放动力学。最后，我们明确胸痛患者心脏生物标志物检测的当代应用，包括将即时检测适当地整合到日常临床应用中。
